Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
N4 Pharma subsidiary agrees work programme for glaucoma treatment
(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London. The AIM-traded firm said ECP105, designed for the post-surgical treatment of glaucoma, has a proprietary siRNA sequence designed to silence the fibrotic gene MRTF-B.
For glaucoma patients who had not responded to conventional medication and required surgery to lower intraocular pressure, fibrosis at the surgery site could be a recurring issue.
That fibrosis often results in the failure of the initial surgery, necessitating additional surgical procedures.
ECP105 offered a potential solution, the company claimed, by being administered via injection into the ocular cavity, effectively switching off the gene responsible for fibrosis.
Importantly, ECP105 distinguishes itself from current off-label treatments involving toxic chemotherapy drugs as it is designed for repeat use to prevent the need for further surgeries.
The upcoming work would revolve around the development and testing of a novel formulation containing Nanogenics' proprietary siRNA sequence.
It said the work aimed to undertake a proof-of-concept in-vivo study demonstrating that a single dose of ECP105 could match the anti-fibrotic effects achieved by the current post-surgical treatment using Mitomycin C, but without the associated cytotoxic side effects.
The advancement held promise for improved treatment outcomes for glaucoma patients and potentially paves the way for a safer and more effective approach to post-surgical care in this field.
"We are very excited for the potential of ECP105, which is a unique product for an unmet clinical need in the ophthalmology market," said chief executive officer Nigel Theobald.
"More than 75 million people worldwide are affected by glaucoma and the total glaucoma treatment market size in 2021 exceeded $5.5bn and is growing.
"A novel product in this space alone represents a good opportunity for Nanogenics and importantly the antifibrotic siRNA sequence can also be used to investigate other fibrotic treatments for liver and lung fibrosis."
At 1308 GMT, shares in N4 Pharma were down 15.78% at 0.95p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.